Thermo Fisher Scientific has been racking up deals over the past few years to boost its diagnostics capabilities. Its latest target? Sequencing giant Illumina, to the tune of $30 billion.
Thermo Fisher has put forward a $30 billion all-stock offer, according to an unnamed source with knowledge of the matter, StreetInsider reported. Illumina, which notched $600 million in Q2 revenues, has a $25 billion market cap, and gained as much as 8% on news of the acquisition proposal. Analysts are critical of the prospects of the deal.
In April 2012, Illumina successfully fought off a $6.7 billion hostile takeover attempt by Roche ($RHHBY), which grew from the initial $5.7 billion offer the Big Pharma proposed in January. Illumina and its shareholders rejected the deal because the price was too low.
Thermo Fisher, with a $61 billion market cap, reels in about $17 billion in revenues annually. It has made a string of acquisitions in the last few years and filed a Form S-3 in March, registering a mixed securities shelf for “general corporate purposes” that “may include the acquisition of companies and businesses.”
Most recently, Thermo Fisher picked up FEI and its electron microscopy technology in a $4.2 billion transaction, while in March, it closed its $1.3 billion purchase of Affymetrix, expanding its drug research and genetic analysis capabilities in the process. Prior to that, the company acquired bioprocessing firm Advanced Scientifics for $300 million in 2015 and Life Technologies for $13.6 billion in 2014, adding it to its Life Sciences Solutions Group.
By Amirah Al Idrus
Source: Fierce Biotech
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.